Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030
To order this detailed 350+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Key Inclusions
§
A detailed assessment
of the current market landscape, including information on drug developer(s),
phase of development (marketed, clinical and preclinical / discovery stage) of
lead candidates, target immune checkpoints, their respective mechanisms of
action (inhibitory or stimulatory), type of therapeutic modality used
(monoclonal antibody, antibody fragment, small molecule and others), route of
administration (intravenous, subcutaneous, oral and others), target disease
indication, target therapeutic area and type of therapy (monotherapy,
combination therapy and both).
§
A detailed analysis
of more than 590 completed, ongoing and planned clinical studies of next
generation immune checkpoint inhibitors and stimulators, highlighting prevalent
trends across various relevant parameters, such as current trial status, trial
registration year, phase of development, study design, leading industry
sponsors / collaborators (in terms of number of trials conducted), trial
focus, type of target, target indication(s), target therapeutic area(s),
enrolled patients population and regional distribution.
§
Detailed profiles of
developers of next generation immune checkpoint modulators (shortlisted on
the basis of the number of pipeline products), featuring an overview of the
company, its financial information (if available), a detailed description
of its product portfolio and recent collaborations. In addition, each profile
includes an informed future outlook.
§
An in-depth analysis
of more than 490 grants that have been awarded to research institutes engaged
in next generation immune checkpoint therapy-related projects, in the period
between 2016 and 2019 (till November), including analysis based on important
parameters, such as year of grant award, amount awarded, administration
institute center, funding institute center, support period, type of grant
application, purpose of grant award, grant mechanism, popular target immune
checkpoints, responsible study section, focus area, prominent program officers,
and type of recipient organizations. It also features a detailed analysis based
on the types of target immune checkpoints and therapeutic areas, along with a
multivariate grant attractiveness analysis based on parameters, such as grant
amount, support period, type of grant application and number of disease
indications under investigation.
§
An analysis of the
partnerships that have been established in the recent past, covering R&D
collaborations, licensing agreements (specific to affiliated technology
platforms and product candidates), product development and commercialization
agreements, clinical trial agreements, manufacturing agreements, mergers and
acquisitions, manufacturing and service agreements, and other relevant types of
deals.
§
An insightful
competitiveness analysis of biological targets, featuring a [A]
three-dimensional bubble representation that highlights the targets that are
being evaluated for next generation immune checkpoint therapy development, taking
into consideration the number of lead molecules based on a particular target,
phase of development of candidate therapies, number of grants and number of
publications [B] a five-dimensional spider-web analysis, highlighting the most
popular immune checkpoint targets.
§
An analysis of the
big biopharma players engaged in this domain, featuring a heat map based on
parameters, such as number of therapies under development, target disease
indications, partnership activity and target portfolio.
§
Informed estimates of
the existing market size and the future opportunity for next generation immune
checkpoint inhibitors and stimulators, over the next decade. Based on multiple
parameters, such as disease prevalence, anticipated adoption of next generation
checkpoint modulator therapies and their likely selling price, we have provided
informed estimates on the evolution of the market for the period 2020-2030.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
- Target
Disease Indication
§
Breast Cancer
§
Chronic Lymphocytic Leukemia
§
Colorectal Cancer
§
Head and Neck Cancer
§
Lung Cancer
§
Lupus Nephritis
§
Melanoma
§
Multiple Myeloma
§
Primary Sjögren's Syndrome
§
Others
- Target
Immune Checkpoint
§
B7-H3
§
CD38
§
CD40
§
CD47
§
Others
- Mechanism
of Action
§
Inhibitory
§
Stimulatory
- Therapeutic
Modality
§
Monoclonal Antibody
§
Small Molecule
- Type
of Therapy
§
Monotherapy
§
Combination Therapy
- Route
of Administration
§
Intravenous
§
Subcutaneous
§
Others
- Key
Geographical Regions
§
North America
§
Europe
§
Asia-Pacific and the Rest of the World
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/303/request-sample.html
Key Questions Answered
§
Who are the leading
industry players engaged in the next generation immune checkpoint inhibitors
and stimulators market?
§
What are the most
important next generation immune checkpoint targets?
§
For which disease
indications are next generation immune checkpoint therapies being developed?
§
What are the key
factors that are likely to influence the evolution of this market?
§
What kind of
initiatives have been undertaken by big pharma players engaged in this domain?
§
Which partnership
models are commonly adopted by stakeholders in this industry?
§
How is the current
and future market opportunity likely to be distributed across key market
segments?
You may also be interested in the following titles:
1.
Neoantigen
Targeted Therapies Market, 2019-2030
2.
Bispecific
Antibody Therapeutics Market (4th Edition), 2019-2030
3.
Global
Stem Cells Market: Focus on Clinical Therapies, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Comments
Post a Comment